Related Experiment Video
Updated: Jun 19, 2026
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Quantifying the efficacy-effectiveness gap in first line treatment of metastatic melanoma
Yago Garitaonaindia1, Adam A Luczak2, Christina H Ruhlmann3
1National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Purpose:
Pivotal phase III trials underpin regulatory approval of immunotherapy (IO) and BRAF/MEK inhibitors (BRAF/MEKi) in metastatic melanoma (MM). However, how trial-derived efficacy benchmarks translate into real-world effectiveness across eligibility strata remains insufficiently quantified.
Methods:
We conducted a nationwide registry-based cohort study using the Danish Metastatic Melanoma Database, including patients with stage IV MM treated in first line with anti-PD-1 monotherapy, anti-PD-1/anti-CTLA-4, or BRAF/MEKi between 2014 and 2023. Real-world outcomes were compared with reconstructed pseudo-individual patient data from pivotal trials as regulatory efficacy benchmarks. Trial eligibility was defined using key exclusion criteria from pivotal studies. Overall survival (OS), progression-free survival (PFS), and melanoma-specific survival (MSS) were analyzed using Kaplan-Meier and Cox regression methods.
Results:
Among 1909 patients, 41.7-44.9% of IO-treated and 74.3% of BRAF/MEKi-treated patients were trial-ineligible. In eligible populations, IO outcomes mirrored regulatory benchmarks. In contrast, trial-ineligible patients experienced substantial effectiveness deviations, with significantly higher mortality hazards for anti-PD-1 monotherapy (OS HR 1.61, 95% CI 1.39-1.86; p < 0.001) and nivolumab/ipilimumab (OS HR 1.30, 95% CI 1.02-1.66; p = 0.035) compared to their reference trials. For BRAF/MEKi, real-world outcomes were inferior to regulatory benchmarks even among trial-eligible patients and were markedly worse in trial-ineligible populations, with hazard ratios >2.5 across OS, MSS, and PFS (all p < 0.001).
Conclusion:
Real-world effectiveness of first-line therapies in MM deviates from regulatory trial benchmarks in trial-ineligible populations, with larger discrepancies for BRAF/MEKi than IO. These findings support population-specific effectiveness evaluation to complement trial-based efficacy estimates and inform health-technology assessment and clinical decision-making.
Insights
Real-world effectiveness of melanoma treatments differs from clinical trial results, especially for patients ineligible for trials. BRAF/MEK inhibitors showed larger gaps than immunotherapies.
Area of Science:
- Oncology
- Clinical Trials
- Real-World Evidence
Background:
- Pivotal trials establish efficacy benchmarks for metastatic melanoma (MM) therapies like immunotherapy (IO) and BRAF/MEK inhibitors (BRAF/MEKi).
- Translating trial efficacy to real-world effectiveness across diverse patient eligibility strata requires quantification.
Purpose of the Study:
- To compare real-world effectiveness of first-line MM therapies against regulatory trial benchmarks.
- To assess effectiveness variations based on patient eligibility for pivotal trials.
Main Methods:
- Nationwide registry-based cohort study (2014-2023) of stage IV MM patients.
- Comparison of real-world outcomes (overall survival, progression-free survival, melanoma-specific survival) with reconstructed trial data.
- Analysis of trial-ineligible vs. trial-eligible populations using Kaplan-Meier and Cox regression.
Main Results:
- Significant proportions of patients were trial-ineligible (41.7-44.9% IO, 74.3% BRAF/MEKi).
- Immunotherapy effectiveness mirrored benchmarks in eligible patients; trial-ineligible groups showed higher mortality.
- BRAF/MEKi real-world outcomes were inferior to benchmarks, particularly in trial-ineligible patients (HR >2.5).
Conclusions:
- Real-world effectiveness deviates from trial benchmarks, especially in trial-ineligible populations.
- Discrepancies are larger for BRAF/MEKi compared to IO.
- Population-specific effectiveness evaluation is crucial for health-technology assessment and clinical decisions.
